We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Best Buy Company Inc. (BBY - Free Report) is a multinational specialty retailer of consumer electronics, home office products, entertainment software and more. Shares of Best Buy have outpaced the industry in the past three months given the company’s sound fundamentals and strategic efforts. In fact, the company reported robust second-quarter fiscal 2021 results, with the top and bottom line rising year-on-year and beating the Zacks Consensus Estimates. Results benefited from growth in products that support stay-at-home practices such as tablets and household appliances. Also, domestic comparable online sales remained strong due to higher traffic and conversion rates. In fact, the company’s domestic comparable online sales increased by triple digits. The company has also been gaining from improved digital services like curbside pickup. Best Buy’s long-term debt as of Aug 1, 2020 decreased by double digits sequentially. In the fiscal second quarter, the company returned about $143 million to shareholders via dividends. Best Buy is aiming high, banking on plans to exploit areas of potential to the fullest.
Jabil, Inc (JBL - Free Report) , is one of the largest global suppliers of electronic manufacturing services (EMS). Jabil’s fourth-quarter fiscal 2020 results benefitted from contract wins in healthcare, automotive, cloud and 5G. Additionally, improving end-market diversification is noteworthy as this boosts investors’ confidence in the company’s ability to increase earnings and revenues. Moreover, a Johnson & Johnson deal is a major growth driver for Jabil. For fiscal 2020, revenues associated with the J&J collaboration are expected between $800 million and $1 billion. Further, the company’s efforts to optimize manufacturing footprint are expected to drive profits. The company has ample liquidity to pursue further growth opportunities in the long haul. Shares of Jabil have outperformed the industry year to date. Jabil’s top-line growth is expected to benefit from strength in healthcare, cloud, retail and industrial.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Top Stock Picks for Week of October 5, 2020
Best Buy Company Inc. (BBY - Free Report) is a multinational specialty retailer of consumer electronics, home office products, entertainment software and more. Shares of Best Buy have outpaced the industry in the past three months given the company’s sound fundamentals and strategic efforts. In fact, the company reported robust second-quarter fiscal 2021 results, with the top and bottom line rising year-on-year and beating the Zacks Consensus Estimates. Results benefited from growth in products that support stay-at-home practices such as tablets and household appliances. Also, domestic comparable online sales remained strong due to higher traffic and conversion rates. In fact, the company’s domestic comparable online sales increased by triple digits. The company has also been gaining from improved digital services like curbside pickup. Best Buy’s long-term debt as of Aug 1, 2020 decreased by double digits sequentially. In the fiscal second quarter, the company returned about $143 million to shareholders via dividends. Best Buy is aiming high, banking on plans to exploit areas of potential to the fullest.
Jabil, Inc (JBL - Free Report) , is one of the largest global suppliers of electronic manufacturing services (EMS). Jabil’s fourth-quarter fiscal 2020 results benefitted from contract wins in healthcare, automotive, cloud and 5G. Additionally, improving end-market diversification is noteworthy as this boosts investors’ confidence in the company’s ability to increase earnings and revenues. Moreover, a Johnson & Johnson deal is a major growth driver for Jabil. For fiscal 2020, revenues associated with the J&J collaboration are expected between $800 million and $1 billion. Further, the company’s efforts to optimize manufacturing footprint are expected to drive profits. The company has ample liquidity to pursue further growth opportunities in the long haul. Shares of Jabil have outperformed the industry year to date. Jabil’s top-line growth is expected to benefit from strength in healthcare, cloud, retail and industrial.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>